Two anti-obesity hopefuls and their safety.
Nicholas T
NT
Bello
Sara C
SC
Campbell
D000328:Adult; D019440:Anti-Obesity Agents / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D001552:Benzazepines / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D015507:Drugs, Investigational / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D005632:Fructose / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006349:Heart Valve Diseases / Q000139:chemically induced; D006801:Humans; D008297:Male; D009765:Obesity / Q000188:drug therapy*; D010645:Phentermine / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D011247:Pregnancy; D013610:Tachycardia / Q000139:chemically induced; D013723:Teratogens / Q000633:toxicity; D000077236:Topiramate; D015431:Weight Loss / Q000187:drug effects
D019440:Anti-Obesity Agents; D001552:Benzazepines; D004338:Drug Combinations; D015507:Drugs, Investigational; C577572:Qnexa; D013723:Teratogens; D000077236:Topiramate; D005632:Fructose; C506658:lorcaserin; D010645:Phentermine